Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
HOTH
HOTH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HOTH News
Hoth Secures Patent to Enhance Immunology IP Portfolio
3d ago
PRnewswire
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics
5d ago
stocktwits
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment
5d ago
PRnewswire
Hoth Therapeutics' GDNF Therapy Outperforms Semaglutide in Preclinical Study
5d ago
Newsfilter
Hoth Therapeutics Reveals GDNF Study Data for Obesity Treatment
6d ago
Benzinga
Hoth Therapeutics Reports Significant Clinical Results from HT-001 Trial in Cancer Patients
Jan 22 2026
Benzinga
Hoth Therapeutics Reports 50% Improvement in Cancer Patients with HT-001 in CLEER-001 Trial
Jan 22 2026
PRnewswire
Hoth Therapeutics Reports Significant Improvement in Cancer Patients' Condition in Clinical Trial
Jan 22 2026
Newsfilter
Hoth Therapeutics Secures China Patent for HT-KIT, Enhancing Oncology Market Protection
Jan 21 2026
PRnewswire
Hoth Therapeutics Secures China Patent for HT-KIT, Enhancing Oncology Market Protection
Jan 21 2026
Newsfilter
Hoth Therapeutics Achieves Positive EU CTIS Conclusion, Near-Term Clinical Trial for Cancer Patients Set to Initiate
Jan 15 2026
PRnewswire
Health Care Stocks Mixed as NYSE Health Care Index Edges Up
Jan 02 2026
Yahoo Finance
Hoth Therapeutics Files New Patents to Expand Oncology Dermatology Platform
Jan 02 2026
NASDAQ.COM
Hoth Therapeutics Files Two US Provisional Patents to Drive Innovation
Jan 02 2026
Yahoo Finance
Hoth Therapeutics Files Two Provisional Patents for Oncology Skin Toxicity Treatments
Jan 02 2026
PRnewswire
Hoth Therapeutics Files Two Patents Addressing Skin Toxicity from Cancer Treatments
Jan 02 2026
Newsfilter
Show More News
